Aptose Biosciences INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Aptose Biosciences Inc. shareholders will vote on a C$2.41 per share cash acquisition by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., following a board recommendation.
Aptose Biosciences selects Ernst & Young as its new independent auditor and calls a reconvened meeting of shareholders for August 22, 2025.
Aptose Biosciences focuses on advancing its tuspetinib-based triplet therapy for AML and seeks shareholder approval for a reverse stock split and stock incentive plan amendment at the upcoming annual meeting.
Aptose Biosciences Inc. will hold a special meeting on January 27, 2025, for shareholders of record as of December 24, 2024.
DEF 14A: Aptose Biosciences Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Aptose Biosciences is asking shareholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and enhance the marketability of its shares.
DEF 14A: Aptose Biosciences Seeks Shareholder Approval for Warrant Share Issuance at Special Meeting
Aptose Biosciences is holding a special meeting on August 15, 2024, to seek shareholder approval for the issuance of common shares underlying certain warrants, as required by Nasdaq listing rules.
Aptose Biosciences is focusing on developing a tuspetinib-containing triplet therapy as a new standard of care for frontline treatment of newly diagnosed acute myeloid leukemia (AML).